<DOC>
	<DOCNO>NCT01019421</DOCNO>
	<brief_summary>The purpose study accept reject hypothesis Lu AE58054 improve cognition functional outcome patient moderate Alzheimer 's Disease , already treatment donepezil .</brief_summary>
	<brief_title>Lu AE58054 Added Donepezil Treatment Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Multi-centre , randomise , double-blind , parallel-group , placebo-controlled , fixed-dose study Lu AE58054 add-on donepezil . The patient probable Alzheimer 's Disease consistent National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDS-ADRDA ) criterion .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>The patient ( applicable legally acceptable representative ( LAR ) different responsible caregiver ) responsible caregiver able read understand Informed Consent Form . The patient knowledgeable reliable caregiver accompany patient clinic visit study . The patient ( applicable LAR different responsible caregiver ) responsible caregiver sign Informed Consent Form . The patient probable AD consistent NINCDSADRDA criterion . The patient man woman , age least 50 year . The patient treat donepezil stable dose least 3 month prior screen . The patient evidence clinically significant neurodegenerative disease serious neurological disorder AD include limited Lewy body dementia , frontotemporal dementia , Parkinson 's disease , Huntington 's disease , major cortical stroke , major head trauma , primary secondary cerebral neoplasia . The patient Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision ( DSMIVTR ) Axis I disorder AD include amnestic disorder , major depressive disorder , delirium , schizophrenia schizoaffective disorder , bipolar disorder , psychosis , panic , post traumatic stress disorder or/and cognitive disorder otherwise specify . The patient clinical radiological finding fulfil standard National Institute Neurological Disorders Stroke Association Internationale pour la Recherch√© et l'Enseignement en Neurosciences ( NINDSAIREN ) criteria vascular dementia . The patient CT MRI evidence hydrocephalus , stroke , spaceoccupying lesion , cerebral infection clinically significant central nervous system disease AD . The patient clinically significant abnormal vital sign . The patient one laboratory value outside normal range , base blood urine sample , , investigator 's judgement , consider clinically significant . The patient clinically significant abnormal ECG . The patient oncological diagnosis ( haematological solid tumour ) currently treat , treatment within 5 year precede screening , still evidence active disease ( patient local dermatological tumour basal squamous cell carcinoma may include ) . The patient 's donepezil therapy likely interrupt discontinue study . The patient disease take medication , investigator 's judgement , could interfere assessment safety , tolerability , efficacy . The patient , investigator 's judgement , unlikely comply clinical study protocol unsuitable reason . The patient member site personnel immediate family . The patient treat his/her ( example , court order ) . The patient patient caregiver unwilling unable abide visit schedule requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Cognition</keyword>
</DOC>